Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 551 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT06151223Recruiting
Pancreatic cancer risk registry for high-risk individuals
This study is a registry for people at high risk for pancreatic cancer. Researchers will collect information over time to learn more about how to detect and prevent the disease.
Rochester, MinnesotaAges 18 years+ - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT04725903Recruiting
Proton beam radiation for high-risk prostate cancer
This trial tests proton radiation therapy for people with high-risk prostate cancer. It may help by delivering radiation in a more targeted way, with the goal of controlling the cancer while reducing exposure to nearby healthy tissue.
Atlanta, GeorgiaAges 18 years+ - NCT07168993Recruiting
Sputum test for lung cancer in high-risk people with lung nodules
This study tests a new, non-invasive test that looks at a sputum (phlegm) sample to see if it can detect lung cancer in people who have a lung nodule. The test might help avoid more invasive procedures and help doctors decide next steps.
Palo Alto, CaliforniaAges 50–80 - NCT06948084RecruitingPhase 2
New drug combo vs usual care for high-risk multiple myeloma
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Coeur d'Alene, IdahoAges 18 years+ - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70 - NCT04278469Recruiting
Study for early breast cancer patients with low-risk genes
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
SeoulAges 19–80 - NCT04700332RecruitingPhase 2
Test of PyL PET/CT for high-risk or returning prostate cancer
This Phase 2 study checks how well a scan called PyL PET/CT can help find prostate cancer that is high-risk or has come back by blood test. The goal is to improve how doctors detect spread and guide the next treatment steps.
Irvine, CaliforniaAges 18 years+ - NCT04476485Recruiting
Predicting breast cancer recurrence after extended hormone therapy
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Harbin, HeilongjiangAges 18–70 - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT04894188Recruiting
Hormone plus radiation before prostate surgery for high-risk cancer
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Douliu City/Huwei Township, Yunlin CountyAges 20–75 - NCT05342792RecruitingPhase 3
Chemo tablets with or without an immune therapy after cancer treatment
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
Guangzhou, GuangdongAges 18–65 - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT03280511RecruitingPhase 2
After surgery chemo sprayed into the abdomen for high-risk colon cancer
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
OdenseAges 18 years+ - NCT03848962Recruiting
Share leftover or collected samples for research
This study helps collect and share human samples (like blood or other specimens) so researchers can do new studies. It’s mainly about providing samples for research use, not testing a treatment on you.
Huntsville, AlabamaAges 1 month–89 years - NCT04472845Recruiting
Shorter or longer breast radiation after surgery for high-risk cancer
This trial compares two schedules of radiation after breast surgery in people with high-risk, node-positive breast cancer. The goal is to see whether giving radiation in 1 week or 2 weeks works well and is safe after standard treatments.
ChandigarhAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05686434RecruitingPhase 2
Osimertinib after surgery for early-stage EGFR-mutated lung cancer
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05746793Recruiting
IVF pregnancy study to prevent pre-eclampsia in high-risk women
This trial studies ways to lower the risk of pre-eclampsia (dangerous high blood pressure in pregnancy) in women who are having a first pregnancy through IVF/ICSI or who have PCOS. It’s aimed at people considered higher risk for pre-eclampsia.
BrusselsAges 18–48 - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT05883969Recruiting
Family play program for infants at high risk for cerebral palsy
This trial tests an early, family-centered play-based intervention for infants who have a high risk of developing cerebral palsy. The goal is to help support early movement and development as soon as possible.
AalborgAges 3 months–1 year
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 551 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.